mRNA |
neratinib |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.006 |
mRNA |
decitabine:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.084 |
0.006 |
mRNA |
Tamoxifen |
GDSC1000 |
pan-cancer |
AAC |
-0.097 |
0.007 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.007 |
mRNA |
Irinotecan |
gCSI |
pan-cancer |
AAC |
-0.16 |
0.007 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.15 |
0.008 |
mRNA |
Cyclopamine |
GDSC1000 |
pan-cancer |
AAC |
-0.14 |
0.008 |
mRNA |
AS605240 |
GDSC1000 |
pan-cancer |
AAC |
-0.092 |
0.008 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.009 |
mRNA |
ceranib-2 |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |